ArticleClinical and experimental immunology2006
Association between mannan-binding lectin and impaired lung function in cystic fibrosis may be age-dependent.
Article in Clinical and experimental immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Airway Epithelium Dysfunction in Cystic Fibrosis and COPD.Mediators of inflammation · 2018Review
- No Strong Relationship Between Components of the Lectin Pathway of Complement and Susceptibility to Pulmonary Tuberculosis.Inflammation · 2015Article
- Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study.Journal of clinical microbiology · 2015Article
- The tumor necrosis factor α (-308 A/G) polymorphism is associated with cystic fibrosis in Mexican patients.PloS one · 2014Article
- Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis.International journal of immunogenetics · 2012Article
- Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.The Journal of pediatrics · 2010Article
- Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis.European journal of human genetics : EJHG · 2010Article
- Mannose-binding lectin deficiency and respiratory tract infection.Journal of innate immunity · 2010Review
- Update on gene modifiers in cystic fibrosis.Current opinion in pulmonary medicine · 2008Review
- Complex two-gene modulation of lung disease severity in children with cystic fibrosis.The Journal of clinical investigation · 2008Article
- Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis.Journal of medical genetics · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An association between mannan-binding lectin (MBL) status and severity of lung function impairment in cystic fibrosis (CF) has been found in several studies, but not in others. To explore the possible basis for discrepancies in the literature, we related both MBL and L-ficolin concentrations to lung function and examined the results in relation to the age of the patients. For patients under 15 years of age, those with MBL < 200 ng/ml had better lung function than those with MBL > 200 ng/ml [median forced expiratory volume in 1 s (FEV(1)), 99% versus 83%; P = 0.05]. For patients over 15 years of age, those with MBL < 200 ng/ml had poorer lung function than those with MBL > 200 ng/ml (median FEV(1), 44% versus 55%; P = 0.1). Also, for the over 15-year-olds, the proportion of patients with FEV(1) values below the median was greater in the MBL-insufficient subgroup (P < 0.04). In other words, relative deficiency of MBL appears to accelerate the age-related decline in lung function in CF patients. No corresponding relationships could be found between L-ficolin concentration and lung function. These findings and interpretation lend support to the potential value of MBL replacement therapy in a small minority of cystic fibrosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.